Logo Image
Opinion|Videos|July 5, 2024

Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication

A pharmacy expert explores infusion-related reactions associated with amivantamab, providing guidance on managing and preventing these reactions, while also addressing the role of split-dosing, premedications, and steroids in the treatment paradigm.

Episodes in this series
  1. Compared to the other EGFR-targeted therapies used in metastatic NSCLC, amivantamab is unique in carrying a risk for infusion-related reactions. What has been your experience with these infusion-related reactions, and what is the typical timing and severity of these reactions?
  1. What preventative strategies do you recommend to help prevent infusion-related reactions with amivantamab?
  2. Please discuss package insert recommendations including split-dosing and premedications, and if patients still experience infusion reactions despite these measures. Please discuss the role of preemptively including steroids as part of routine premedication (particularly when given as monotherapy and not already receiving steroids for pemetrexed purposes).
  3. In your experience and in the context of these toxicities, how do patient-specific factors such as performance status and comorbidities influence the choice of EGFR-targeted therapies?
  4. Please address considerations related to monotherapy vs. combination therapy (either with chemotherapy or other non-chemotherapy agents)

Related to this article

View more